25-Apr-2024
No headlines found.
Globe Newswire (Thu, 21-Mar 7:00 AM ET)
Globe Newswire (Wed, 20-Mar 7:00 AM ET)
Cabaletta Bio to Participate in Upcoming Investor Conferences in March
Globe Newswire (Tue, 27-Feb 8:00 AM ET)
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
Globe Newswire (Thu, 1-Feb 4:30 PM ET)
Cabaletta Bio to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
Globe Newswire (Wed, 31-Jan 8:00 AM ET)
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.
Cabaletta Bio trades on the NASDAQ stock market under the symbol CABA.
As of April 25, 2024, CABA stock price declined to $12.18 with 1,872,905 million shares trading.
CABA has a beta of 2.68, meaning it tends to be more sensitive to market movements. CABA has a correlation of 0.17 to the broad based SPY ETF.
CABA has a market cap of $587.58 million. This is considered a Small Cap stock.
In the last 3 years, CABA stock traded as high as $26.35 and as low as $.59.
The top ETF exchange traded funds that CABA belongs to (by Net Assets): XBI, VTI, IWM, VXF, LABU.
CABA has outperformed the market in the last year with a return of +41.8%, while the SPY ETF gained +23.6%. However, in the most recent history, CABA shares have underperformed the stock market with its stock returning -40.6% in the last 3 month period and -31.8% for the last 2 week period, while SPY has returned +4.1% and -2.1%, respectively.
CABA support price is $12.35 and resistance is $13.57 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CABA stock will trade within this expected range on the day.